NCI has an interest in spurring collaborations between ITCR investigators and PIs from a sister technology development program for new molecular and cellular analysis technology development (IMAT). For the last 3 years we have been able to secure funds for administrative supplements to support new collaborations that bring together complementary technology platforms and methodologies to enhance the respective capabilities you are pioneering in a way that advances cancer research or clinical care.
NCI is again seeking to reserve a small budget to make administrative funds available for supplements by the end of this fiscal year and we would like to make sure that compelling new ITCR-IMAT collaborations are considered for those funds. As such, we are inviting you to consider engaging an investigative team funded by the IMAT program that might offer some intriguing complementarity to your own technology development project. Please note that supplementary award requests may not exceed $50k to each collaborator (direct cost cap) and are offered for only a single year, and are only available to investigators with sufficient time left on your award (i.e. the grant must be actively funded, and not in a period of no-cost extension, to be eligible). The process for being considered will involve the following:
Supplements cannot be awarded during periods of No Cost Extension. Therefore, LOIs should not be submitted for grants that do not have sufficient time remaining in the funded period of the award beyond September 2020.
A listing of the IMAT grants is available here for those interested in identifying a potential collaborator. Please also note that both Tony Dickherber and Juli Klemm are happy to help identify collaboration candidates and facilitate introductions to other teams.